Form 8-K - Current report:
SEC Accession No. 0001213900-24-106646
Filing Date
2024-12-09
Accepted
2024-12-09 07:49:36
Documents
15
Period of Report
2024-12-09
Items
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea0224026-8k_relmada.htm   iXBRL 8-K 28107
2 PRESS RELEASE ISSUED ON DECEMBER 9, 2024 ea022402601ex99-1_relmada.htm EX-99.1 10845
3 GRAPHIC ex99-1_001.jpg GRAPHIC 17674
  Complete submission text file 0001213900-24-106646.txt   240706

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE rlmd-20241209.xsd EX-101.SCH 3012
5 XBRL LABEL FILE rlmd-20241209_lab.xml EX-101.LAB 34240
6 XBRL PRESENTATION FILE rlmd-20241209_pre.xml EX-101.PRE 22357
17 EXTRACTED XBRL INSTANCE DOCUMENT ea0224026-8k_relmada_htm.xml XML 3694
Mailing Address 2222 PONCE DE LEON BLVD. 3RD FLOOR CORAL GABLES FL 33134
Business Address 2222 PONCE DE LEON BLVD. 3RD FLOOR CORAL GABLES FL 33134 646 876 3459
RELMADA THERAPEUTICS, INC. (Filer) CIK: 0001553643 (see all company filings)

EIN.: 455401931 | State of Incorp.: NV | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39082 | Film No.: 241533873
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)